COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,047 Articles (22,627 medRxiv, 8,420 bioRxiv)

Most recent first Previous |  Page 796: Articles 7951-7960  | Next

Persistent cross-species SARS-CoV-2 variant infectivity predicted via comparative molecular dynamics simulation
Rajendran, M., Babbitt, G. A.
10.1101/2022.04.18.488629 — Posted: 2022-04-19
Redox regulation of the SARS-CoV-2 main protease provides new opportunities for drug design
Tittmann, K., Funk, L.-M., Poschmann, G., Chari, A., Rabe von Pappenheim, F., Stegmann, K. M., Dickmanns, A., Eulig, N., Wensien, M., Paknia, E., Heyne, G., Penka, E., Pearson, A. R., Berndt, C., Fritz, T., Bazzi, S., Uranga, J., Mata, R. A., Dobbelstein, M., Hilgenfeld, R., Curth, U.
10.1101/2022.04.18.487732 — Posted: 2022-04-19
Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses using gene expression profiles of chemical and genetic perturbations
Shen, Z., Halberg, A., Fong, J. Y., Guo, J., Song, G., Louie, B., Luedtke, G. R., Visuthikraisee, V., Protter, A., Koh, X., Baik, T., Lum, P. Y.
10.1101/2022.04.18.488682 — Posted: 2022-04-19
Vγ9Vδ2 T cells are potent inhibitors of SARS-CoV-2 replication and exert effector phenotypes in COVID-19 patients
Gay, L., Rouviere, M.-S., Mezouar, S., Richaud, M., Gorvel, L., Foucher, E., Madakamutil, L., La Scola, B., Menard, A., Allardet-Servent, J., Halfon, P., Frohna, P., Cano, C., Mege, J.-L., Olive, D.
10.1101/2022.04.15.487518 — Posted: 2022-04-19
Pathogen- and type-specific changes in invasive bacterial disease epidemiology during the first year of the COVID-19 pandemic in the Netherlands
Steens, A., Knol, M. J., Freudenburg-de Graaf, W., de Melker, H. E., van der Ende, A., van Sorge, N. M.
10.1101/2022.04.19.22273034 — Posted: 2022-04-19
An Evaluation of Prospective COVID-19 Modeling: From Data to Science Translation
Nixon, K., Jindal, S., Parker, F., Reich, N. G., Lee, E. C., Truelove, S., Gardner, L.
10.1101/2022.04.18.22273992 — Posted: 2022-04-19
An optimized flow cytometry protocol for simultaneous detection of T cell activation induced markers and intracellular cytokines: application to SARS-Cov-2 vaccinated individuals
Altosole, T., Rotta, G., Bornheimer, S., Fenoglio, D.
10.1101/2022.04.14.22273819 — Posted: 2022-04-19
Similar viral loads in Omicron infections regardless of vaccination status
Hirotsu, Y., Maejima, M., Shibusawa, M., Natori, Y., Nagakubo, Y., Hosaka, K., Sueki, H., Mochizuki, H., Tsutsui, T., Kakizaki, Y., Miyashita, Y., Omata, M.
10.1101/2022.04.19.22274005 — Posted: 2022-04-19
Validation of Reduced S-gene Target Performance and Failure for Rapid Surveillance of SARS-CoV-2 Variants
Clark, C., Schrecker, J., Hardison, M., Taitel, M. S.
10.1101/2022.04.18.22273989 — Posted: 2022-04-19
Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial
Follmann, D., Janes, H. E., Buhule, O. D., Zhou, H., Girard, B., Marks, K., Kotloff, K., Desjardins, M., Corey, L., Neuzil, K. M., Miller, J. M., El Sahly, H. M., Baden, L. R.
10.1101/2022.04.18.22271936 — Posted: 2022-04-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).